Product News

Share this article:

Johnson & Johnson subsidiary Centocor Ortho Biotech received FDA approval for Simponi, an injectable treatment for arthritis caused by immune-system disorders. According to an AP report, the drug is a potential blockbuster, and a follow-up to Remicade, a multibillion-dollar seller. Simponi will be marketing in the US by J&J, and in Europe by Schering-Plough.

 

FDA authorized a relaxed indication and distribution of Roche's and GlaxoSmithKline's antiviral drugs – Tamiflu and Relenza, respectively – in order to combat swine flu. Public health officials and volunteers will be allowed to distribute the meds, and both drugs will be available off-label, based on FDA's “Emergency Use Authorization” provision.

 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.